ArticlePloS one2026
The reliability and validity of rehabilitation set of the international classification of functioning, disability, and health in assessing Chinese tumor patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThere is currently no comprehensive scale suitable for assessing the rehabilitation progress of Chinese tumor patients. This study aimed to evaluate the psychometric properties of the Rehabilitation Set of the International Classification of Functioning, Disability, and Health for that purpose.
methodsThe Chinese version of the International Classification of Functioning, Disability, and Health's Rehabilitation Set (ICF-RS) was used by trained health professionals to assess 1055 Chinese tumor patients. The internal consistency of the responses was assessed in terms of Cronbach's alpha coefficient. Construct validity was explored through factor analysis. Test-retest reliability, inter-rater reliability, and criterion validity were evaluated using a subset of 121 patients. Criterion validity was quantified by correlating the scores with those generated using the Hospital Anxiety and Depression scale (HADS), the Eastern Cooperative Oncology Group (ECOG) performance status evaluation and the modified Barthel Index (MBI).
resultsThe Cronbach's alpha for the rehabilitation set's scores was 0.87, indicating good internal consistency. The test-retest reliability analysis showed that most categories had an intraclass correlation coefficient in excess of 0.75, suggesting good reliability when the rehabilitation set is applied with tumor patients. Inter-rater reliability also demonstrated intraclass correlation greater than 0.75 for most categories. Construct validity was supported by the finding that 18 categories had factor loadings exceeding 0.40. After removing categories with lower factor loadings, the cumulative variance explained increased to 44.6% for the Activity and Participation component and 57.3% for the Body Functions component. Criterion validity was supported by significant associations with established instruments. Specifically, 66.7% (20/30) of the ICF-RS categories correlated significantly with the MBI, with effect sizes (r) ranging from 0.19 to 0.52 (p < 0.05). In contrast, only 10% (3/30) of categories demonstrated significant correlations with the ECOG ratings (ρ = 0.21-0.22, p < 0.05). Furthermore, categories related to emotional functions and psychological demands showed significant correlations with the HADS, with moderate effect sizes (ρ = 0.37-0.41, p < 0.001).
conclusionsThe Chinese version of the ICF-RS exhibits promising psychometric properties in tumor patients, providing preliminary evidence for its clinical application. It demonstrates good internal consistency, high test-retest reliability and reliable inter-rater consistency. The moderate correlation with MBI ratings and HADS scale scores, along with the distinct factors identified through factor analysis, further supports the instrument's validity and utility when applied to this population. The data confirm that the ICF-RS is a reliable tool for assessing tumor patients' functioning and disability. However, the construct validity results recommend further work before the instrument is widely used with tumor patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.